The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice

Ivanovski, Ognen; Nikolov, Igor G; Joki, Nobuhiko; Caudrillier, Axelle; Phan, Olivier; Mentaverri, Romuald; Maizel, Julien; Hamada, Yasuhiro; Nguyen-Khoa, Thao; Fukagawa, Masafumi; Kamel, Said; Lacour, Bernard; Drüeke, Tilman B; Massy, Ziad A

doi:10.1016/j.atherosclerosis.2008.10.043

The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice

Journal

Atherosclerosis

Date Issued

2009-07

Author(s)

Joki, Nobuhiko

Caudrillier, Axelle

Phan, Olivier

Mentaverri, Romuald

Maizel, Julien

Hamada, Yasuhiro

Nguyen-Khoa, Thao

Fukagawa, Masafumi

Kamel, Said

Lacour, Bernard

Drüeke, Tilman B

Massy, Ziad A

DOI

10.1016/j.atherosclerosis.2008.10.043

Abstract

Secondary hyperparathyroidism of chronic kidney disease promotes vascular calcification. Calcimimetics reduce serum parathyroid hormone, calcium (Ca), and phosphorus by calcium-sensing receptor (CaR) activation. Here we examined possible effects of the calcimimetic R-568 (R-568) on the progression of aortic calcification and atherosclerosis in apoE(-/-) mice with chronic renal failure (CRF) and the potential implication of aortic smooth muscle cell CaR.